LINKER-MM1
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma (LINKER-MM1)
What will happen during the trial?
The study is looking at several other research questions, including:
- Side effects that may be experienced by people receiving linvoseltamab
- How linvoseltamab works in the body
- How much linvoseltamab is present in the blood
- How linvoseltamab may work to treat cancer
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 309 patients (estimated)
- Sponsors
- Regeneron Pharmaceuticals
- Tags
- Bispecific Antibody, CD3, B-Cell Maturation Antigen (BCMA)
- Trial Type
- Treatment
- Last Update
- SparkCures ID
- 1016
- NCT Identifier
- NCT03761108
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.